Plasmid, mRNA, & Viral Vector Manufacturing

The rapid rise of gene therapies and genetic medicines is transforming the pharmaceutical landscape, driving unprecedented demand for scalable and reliable manufacturing solutions. Central to this shift are three interconnected platforms—plasmid DNA, mRNA, and viral vectors—each playing a critical role in the development and delivery of advanced therapies.

Plasmid DNA serves as a foundational starting material, acting as a template for both mRNA production and viral vector generation. As these therapies move from early development to commercial scale, ensuring consistent quality, purity, and supply of plasmid DNA has become a major industry challenge.

At the same time, mRNA manufacturing requires precise transcription and formulation processes, while viral vector production introduces additional complexity in scaling, process control, and regulatory compliance.

Successfully integrating these workflows is essential for advancing next-generation therapies, enabling manufacturers to meet growing demand while maintaining safety, efficiency, and product integrity across the development lifecycle.